search results for 
Logo

Reconciliation to Group net income

The Group’s U.S. GAAP financial results as of December 31, 2013 include a special item. Net income attributable to shareholders of Fresenius SE & Co. KGaA in 2013 was adjusted for the integration costs for Fenwal. Group net income in 2012 was adjusted for a non-taxable investment gain and other one-time costs at Fresenius Medical Care, as well as one-time costs related to the public takeover offer (offer) to the shareholders of Rhön-Klinikum AG. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

RECONCILIATION



€ in millionsQ1 – 4 / 2013 before special itemsFenwal integration costsQ1 – 4 / 2013 according to U.S. GAAP (incl. special items)Q1 – 4 / 2012 before special itemsNon-taxable investment gain at Fresenius Medical CareOne-time costs related to the takeover offer to the shareholders of Rhön- Klinikum AGOther one-time costs at Fresenius Medical CareQ1 – 4 / 2012 according to U.S. GAAP (incl. special items)
Sales20,33120,33119,29019,290
EBIT3,045-542,9913,0750-6-862,983
Investment gain000109109
Interest result-584-584-666-666
Other financial result000-35-35
Net income before taxes2,461-542,4072,409109-41-862,391
Income taxes-68314-669-7021231-659
Net income1,778-401,7381,707109-29-551,732
Less noncontrolling interest-727-727-769-7538-806
Net income11,051-401,01193834-29-17926

€ in millionsQ1 – 4 / 2013 before special itemsFenwal integration costsQ1 – 4 / 2013 according to U.S. GAAP (incl. special items)Q1 – 4 / 2012 before special itemsNon-taxable investment gain at Fresenius Medical CareOne-time costs related to the takeover offer to the shareholders of Rhön- Klinikum AGOther one-time costs at Fresenius Medical CareQ1 – 4 / 2012 according to U.S. GAAP (incl. special items)
Sales20,33120,33119,29019,290
EBIT3,045-542,9913,0750-6-862,983
Investment gain000109109
Interest result-584-584-666-666
Other financial result000-35-35
Net income before taxes2,461-542,4072,409109-41-862,391
Income taxes-68314-669-7021231-659
Net income1,778-401,7381,707109-29-551,732
Less noncontrolling interest-727-727-769-7538-806
Net income11,051-401,01193834-29-17926

STATEMENT OF INCOME (SUMMARY)


€ in millions20132012ChangeChange in constant currency
Sales20,33119,2905%8%
Cost of goods sold-13,948-13,002-7%-10%
Gross profit6,3836,2882%4%
Selling, general, and administrative expenses-3,044-3,000-1%-4%
Research and development expenses-348-305-14%-17%
EBIT (operating result)2,9912,9830%3%
Investment gain0109-100%-100%
Net interest-584-66612%10%
Other financial result0-35100%100%
Income taxes-669-659-2%-5%
Noncontrolling interest in profit-727-80610%7%
Net income (before special items)11,05193812%14%
Net income21,0119269%11%
Earnings per ordinary share in € (before special items)15.885.428%11%
Earnings per ordinary share in €25.665.356%8%
EBITDA3,8343,7592%5%
Depreciation and amortization8437769%12%

€ in millions20132012ChangeChange in constant currency
Sales20,33119,2905%8%
Cost of goods sold-13,948-13,002-7%-10%
Gross profit6,3836,2882%4%
Selling, general, and administrative expenses-3,044-3,000-1%-4%
Research and development expenses-348-305-14%-17%
EBIT (operating result)2,9912,9830%3%
Investment gain0109-100%-100%
Net interest-584-66612%10%
Other financial result0-35100%100%
Income taxes-669-659-2%-5%
Noncontrolling interest in profit-727-80610%7%
Net income (before special items)11,05193812%14%
Net income21,0119269%11%
Earnings per ordinary share in € (before special items)15.885.428%11%
Earnings per ordinary share in €25.665.356%8%
EBITDA3,8343,7592%5%
Depreciation and amortization8437769%12%